42 results about "GLYAT" patented technology

The invention relates to a recombinant corynebacterium crenatum to enhance the expression of N-acetyl glutamic acid kinase and the application thereof, which belongs to the technical field of gene engineering. The classification and nomenclature of the recombinant corynebacterium crenatum to enhance the expression of N-acetyl glutamic acid kinase is corynebacterium crenatum SYPA/pJC1-tac-argB with an access number of CCTCC NO: M 208133; The application is as follows: using a key enzyme N-acetyl glutamic acid kinase from corynebacterium crenatum pathway arginine to construct a corynebacterium crenatum expression vector pJC1-tac-argB; introducing the corynebacterium crenatum expression vector pJC1-tac-argB into corynebacterium crenatum SYPA by electrotransformation to obtain the recombinant corynebacterium crenatum SYPA/pJC1-tac-argB; and excessively expressing N-acetyl glutamic acid kinase, which greatly enhances the utilization rate of a precursor glutamic acid and allows the metabolic flow to flow to the arginine synthesis pathway, weakens the synthesis of proline, achieves the purpose of improving the output of arginine and the output of arginine is increased by 23.4 percent than C. crenatum SYPA.

The invention relates to a high-specific activity L-glutamate oxidase gene multisite mutant, and a preparation method and application thereof. The nucleotide sequence of the mutant is shown as SEQ ID No 64; the amino acid sequence of encoded protein is shown as SEQ ID No 65. A molecular in vitro recombination technique is used for screening high-specific activity L-glutamate oxidase gene; through vector building, enzyme activity screening, multisite mutation techniques and the like, the high-specific activity L-glutamate oxidase gene multisite mutant is obtained through preparation. The multisite mutant contains 9 different mutation sites on the same gene, so that the oxidation specificity and the specific activity of the multisite mutant on L-glutamic acid are greatly improved; the multisite mutant can be used for detecting the content of the L-glutamic acid in food.

An alpha-amylase mutant with improved enzymatic activity and applications thereof are disclosed and belong to the technical field of genetic engineering and microbial engineering. The mutant is obtained by mutating the amino acid at the number 82 site of alpha-amylase having an amino acid sequence of SEQ ID NO.1 from lysine into glutamic acid or mutating the amino acid at the number 405 site of the alpha-amylase having an amino acid sequence of SEQ ID NO.1 from serine into arginine or simultaneously mutating the amino acid at the number 82 site of the alpha-amylase having an amino acid sequence of SEQ ID NO.1 from lysine into glutamic acid and mutating the amino acid at the number 405 site from serine into arginine. The enzymatic activity of alpha-amylase in a fermentation solution can beincreased to 474.7 U/mL by fermenting a recombinant Bacillus subtilis engineering bacterium for 48 h, with the recombinant Bacillus subtilis engineering bacterium being constructed by adopting a genecoding the mutant as a target gene, adopting pHY300PLK as an expression vector, and adopting Bacillus subtilis WS5 as an expression host.

The present invention discloses one kind of gene recombinant human cytomegalovirus fusion protein pp150/MDBP and its preparation process and application, and relates to gene engineering technology, preventing vaccine, diagnosis reagent and other technology. The recombinant fusion protein pp150/MDBP is fusion protein formed through connecting serially the 197th amino acid in the 495-691 amino acid segment of human cytomegalovirus pp150 and the 64th amino acid in the 538-601 amino acid segment of MDBP protein. The 197th amino acid pp150 in the N-terminal of the fusion protein and the 64th amino acid of MDBP protein in the C-terminal of the fusion protein are connected through two amino acids including one Leu and one Glu, and the fusion protein has one increased Met and has whole length of 264 amino acids. The fusion protein is used in detecting human cytomegalovirus antibody and antigen, preparing antibody and protein chip, vaccine, ELISA detecting kit and other products.

The invention discloses four mutants of D-carbamoyl hydrolase and application to manufacture D-p-hydroxybenzene glycine in the biological engineering domain, which is characterized by the following: mutating the amino acid at 18th position of mutation enzyme 1 from alanine into threonine and tyrosine at 30th position of mutation enzyme 2 to asparagine; switching the lysine at 30th of mutation enzyme 2 into glutacid; overlapping three mutation positions; obtaining the mutation enzyme 4.

The present invention discloses a corynebacterium glutamate for synthesizing geraniol and a construction method and application of corynebacterium glutamate. The construction method of corynebacteriumglutamate comprises the following steps: connecting a saccharomyces cerevisiae-derived mutant geranyl pyrophosphate synthase gene ERG20<F96W-N127W> and a valerian-derived geranol synthase gene tVoGEStruncated through cutting off of C-terminal 53 amino acid residues by fusion PCR, adding a ribosome binding site sequence to a homologous region, inserting SacI and XbaI enzyme cutting sites of a corynebacterium glutamate expression plasmid pEC-XK99E to obtain a plasmid 1; converting the plasmid 1 into corynebacterium glutamate to obtain corynebacterium glutamate 1 for synthesizing geraniol. Theconstruction method provides more precursors and short fermentation time (42 to 48 hours) for the synthesis of geraniol, and corresponding by-products are not detected out by GC-MS detection.

The invention discloses a cytochrome P450 BM-3 variant enzyme, a coding gene and application of the cytochrome P450 BM-3 variant enzyme. An amino acid sequence of the variant enzyme is shown in SEQ ID NO.1; three mutational sites are added on the basis of the cytochrome P450 BM-3 (F87/A74G/L188Q) variant enzyme, namely aspartic acid (GAT) at the 168th site mutates into aminocaproic acid (CTT), glutamic acid (GAA) at the 435th site mutates into threonine (ACG), and valine (GTG) at the 445th site mutates into aminopropionic acid (GCG). Compared with male parent enzyme and protoenzyme, the variant enzyme disclosed by the invention has high affinity with substrate and the efficiency of catalyzing benzazole to generate indigo is higher.

The present disclosure provides novel compositions and methods for the production and use of polynucleotide sequences encoding a glycine N-acyltransferase protein (GLYAT, GLYATL 1, GLYATL 2, and GLYATL 3) for the biosynthesis of N-acylglycine biosurfactants within a heterologous expression system.

The invention provides glutamyltranspeptidase for synthesizing gamma-polyglutamic acid and a coding gene thereof. The protein molecule of the glutamyltranspeptidase has the amino acid sequence as shown in SEQ ID NO: 2; and the gene of the glutamyltranspeptidase has the nucleotide sequence as shown in SEQ ID NO: 1. The invention also discloses a method for synthesizing the gamma-polyglutamic acid by utilizing recombinant glutamyltranspeptidase. By adopting the method, the gamma-polyglutamic acid is synthesized by utilizing the recombinant glutamyltranspeptidase and taking glutamine monomers as raw materials. The glutamyltranspeptidase can be used for synthesizing the gamma-polyglutamic acid by taking the glutamine monomers as the raw materials, thus having importance significance in enriching glutamyltranspeptidase family members and developing a new gamma-polyglutamic acid synthesis route.

The invention provides a heat-resistant beta-galactosidase mutant with transglycosylation. The mutant is obtained through the steps that beta-galactosidase (BgaB) catalyzes an amino acid site E303 to be mutated into cysteine (Cys) in a site-directed mode from original glutamic acid (Glu), and a cysteine sulfhydryl group is oxidized into -SOO<->. The invention further designs a preparation method and application of the mutant. Beta-galactosidase (BgaB) derived from bacillus stearothermophilus serves as an object, a method combining a site-directed mutant with chemical modification is adopted, the functional evolution efficiency of transglycosylation is significantly improved, the synthesis quantity of galactooligosaccharide is improved, the synthesis quantity of galactooligosaccharide is improved to 11.5% from 0% of wild-type enzyme under a medium temperature and neutral environment, limitation of reacting under an acid environment in the prior art is broken through, and meanwhile hydrolysis of a substrate or a product is avoided when galactooligosaccharide is synthesized.

The present invention relates to a signal peptide and application thereof in recombinant bacteria for producing L-glutamic acid from konjaku flour, and belongs to the field of genetic engineering and enzyme engineering. The screened and codon-optimized signal peptide, namely SEQ ID No.1 is fused, by molecular cloning and genetic engineering techniques, with B. subtilis CCTCC M 209200-sourced beta-mannanase for construction of an expression vector for expressing in L-glutamic acid high-yield production bacterial stain. For the first time, the signal peptide is reported, wherein the signal peptide can be used for mediation of recombinant bacteria Brevibacterium tianjinese SW07-1 / pMSPman, which is capable of secreting the beta-mannanase, for producing the L-glutamic acid by fermentation of the chip konjaku flour, and the yield of a 5L fermentor is 65g / L under the condition of addition of an optimal carbon source.

The genetic medicine for treating cancer and other diseases characterized by run-off cell division includes carrier and active component, and the active component contains mutant human alpha-tubulin gene with the nucleotide sequence encoding the 254 position amino acid Glu defected or displaced by nucleotide sequence of any other amino acid. The preparation process includes in vitro change of wild human alpha-tubulin gene or its fragment to displace or delete alpha-tubulin Glu 254 and obtain mutant alpha-tubulin gene; and implanting vector in expressable mode. When medicine is guided to the disease part, the expressed mutant alpha-tubulin and wild beta-tubulin are combined to form dimer and assemble microtubule. This will block disassembly of microtubule, break dynamic microtubule instability, disturb mitosis and treat cancer and other diseases characterized by run-off cell division.

A TRAIL cell-penetrating peptide (CPPs)-like mutant MuR6 and a preparation method and the application thereof. The amino acid sequence of the mutant is SEQ ID NO: 2. The mutant selectively transforms the amino acid coding sequence of No. 114-119 of the outer fragment of the TRAIL wild-type protein cell membrane from VRERGP to RRRRRR, i.e., mutates valine into arginine on the 114^th coding sequence, glutamic acid into arginine on the 116^th coding sequence, glycine into arginine on the 118^th coding sequence and proline into arginine on the 119^th coding sequence, turning the coding sequence of N-terminal of the mutant protein into that of six arginines and making it a protein containing CPPs-like structure. Having a superior therapeutic effect on different types of tumor, the TRAIL mutant is a new generation of high-efficient drug for inducing tumor apoptosis of much potential.

The invention relates to a recombinant zymoprotein having high activity and specific GT. According to the invention, the 80th to 368th amino acids of Inner Mongolia cow thymus GT proteins, the smallest water-soluble part with activity of GT, are employed. To further improve water-solubility and enzyme reaction activity of recombinant GT, through molecular designing and gene engineering reconstruction of natural proteins, the 160th amino acid of GT proline is modified to be lysine, the 241st amino acid of GT glutamic acid is modified to be glutamine, and therefore, recombinant zymoprotein withstronger enzymatic activity is obtained; the obtained recombinant zymoprotein has enzymatic activity 8 to 10 times that of existing zymoprotein and is applicable to the medical field of tumor treatment.

The nucleic acid sequence of the human Excitatory Amino Acid Transporter-2 Gene (hEAAT2) promoter, a nucleic acid sequence that hybridizes to the hEAAT2 promoter nucleic acid sequence under stringent hybridization conditions, and a nucleic acid sequence that is functionally equivalent to the hEAAT2 promoter sequence are provided, as are vectors containing these nucleic acid sequences. In addition, methods for the use of these nucleic acids to achieve tissues- or cell-specific gene expression are provided, as are methods for the use of these hEAAT2 promoter nucleic acids to identify agents that can modulate glutamate transport or the activity of the glutamate promoter. Such agents may be useful in the prevention, palliation or treatment of neurodegenerative and/or cerebrovascular diseases.

The increase in antibacterial resistance has created the demand for new antibiotics. The present invention relates to a more potent antibiotic that targets the enzyme glutamate racemase from known glutamate racemase inhibitors. Glutamate racemase catalyses the interconversion of L-glutamate to D-glutamate, making D-glutamate available, which is required for bacterial peptidoglycan biosynthesis. Knockout mutations have shown glutamate racemase to be necessary for bacterial cell survival and, before the present invention, no antibiotic on the market targeted this enzyme. The present invention relates to new, ligand based glutamate racemase inhibitors, developed using software to extract a pharmacophore model from a group of known glutamate racemase inhibitors. Forty-seven (47) known inhibitors were collected from the literature and several pharmacophore models were extracted therefrom. The functional groups common to all the known inhibitors were included in a pharmacophore model that described the requirements for glutamate racemase inhibition with 82% accuracy. Of these models, one was found to describe the requirements for glutamate racemase inhibition with 82% accuracy. The model was used to search databases of commercially available chemical compounds and 2-(2-(1H-indol-3-yl)ethylamino)-4-oxo-4-p-tolylbutanoic acid and 2-(2-(1H-indol-3-yl)ethylamino)-4-(4-fluorophenyl)-4-oxobutanoic acid were identified as showing antibacterial activity. These compounds were assayed against S. pneumoniae and were shown to have antibacterial activity against the non-virulent strain R6 and against a multidrug resistant strain.

A TRAIL cell-penetrating peptide (CPPs)-like mutant MuR5 and a preparation method and the application thereof. The amino acid sequence of said mutant is SEQ ID NO: 2. The TRAIL CPPs-like mutant selectively transforms the amino acid coding sequence of No. 114-118 of the outer fragment of the TRAIL wild-type protein cell membrane from VRERG to RRRRR, i.e., mutates valine into arginine on the 114^th coding sequence, glutamic acid into arginine on the 116^th coding sequence and glycine into arginine on the 118^th coding sequence, turning the coding sequence of N-terminal of the mutant protein into that of five arginines and making it a protein containing CPPs-like structure. Having a superior therapeutic effect on different types of tumor, the TRAIL CPPs-like mutant is a new generation of high-efficient drug for inducing tumor apoptosis of much potential.